Skip to main content
OpenTrials
Completed

NCT Number: NCT02864017

Immuno Nutrition by L-citrulline for Critically Ill Patients

The main objective of this study is to demonstrate that the only administration of L-citrulline, can improve immune functions in critically ill patients at high risk of nosocomial infection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Angers, Angers, France

Loading trial locations.

About this study

This is a multicentric therapeutic trial, randomized and double blind: standard enteral nutrition plus L-citrulline (5 grams/12 Hours for 5 days from the admission in Intensive Care Unit (ICU)) versus standard enteral nutrition plus placebo.

Methods-Patients: Non-surgical patients admitted in medical intensive care unit, under mechanical ventilation for an expected duration > 2 days, without severe sepsis or septic shock, will be enrolled. Symptoms leading for ICU admission ongoing for five days maximum. On admission (before treatment), the severity will be evaluated with the Sepsis-related Organ Failure Assessment (SOFA) score together with an assessment of plasmatic arginine, cytokines (InterLeukin-6 (IL6) ), and expression of Human Leukocyte Antigen - antigen D Related (HLA-DR) by monocytes. The same evaluation will be repeated on day 3 (during treatment) and on day 7 (after treatment).

The enrolment of 100 patients is statistically enough to demonstrate a decreased SOFA scores in the L-citrulline group as compared to the placebo group on day 7.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age > 18 years
  • medical patient (absence of recent surgery or trauma)
  • initial aggression < 5 days
  • mechanically ventilated with expected duration of mechanical ventilation > 2 days
  • exclusive enteral nutrition
  • absence of previous immunosuppression

Exclusion criteria

  • severe sepsis
  • septic shock
  • obesity defined as BMI above 40
  • pregnancy

Treatment and study plan

Enteral nutrition

Procedure

L-citrulline

Dietary Supplement

Placebo

Dietary Supplement

Primary outcomes

  1. Organ failure score comparison D7

    Time frame: At day 7

    Organ failure score (SOFA score) on day 7 in the L-citrulline group as compared to the placebo group

Secondary outcomes

  1. Organ failure score comparison D3

    Time frame: At day 3

    Organ failure score (SOFA score) on day 3 in the L-citrulline group as compared to the placebo group

  2. SOFA score evolution between randomisation and D7

    Time frame: up to 7 days

    Binary criterion of success or failure :

    • Success is defined by: an improved SOFA score of at least 2 points from randomization to Day 7 or an improvement in the general condition yielding the release of the unit;
    • Failure is defined by an improved SOFA score but less than 2 points, no improvement or worsening of the SOFA score from randomization to Day 7 or the patient's death before J7;
  3. Expression of HLA-DR

    Time frame: At day 7

    Expression of HLA-DR in the L-citrulline group as compared to the placebo group

  4. Plasmatic concentration of IL6

    Time frame: At day 7

    Comparison of the plasmatic concentration of interleukin-6 between the L-citrulline group and the placebo group

  5. HLA-DR

    Time frame: At day 7

    Comparison of the percentage of expression of monocytic HLA-DR between the L-citrulline group and the placebo group

  6. Plasmatic concentration of L-arginine

    Time frame: At day 7

    Comparison of the plasmatic concentration of L-arginine and its metabolites between the L-citrulline group and the placebo group

  7. Incidence of nosocomial infections

    Time frame: during the stay in the ICU, an average of 7 days

    Comparison between the L-citrulline group and the placebo group

  8. Length of stay

    Time frame: during the stay in hospital, up to 28 days

    Length of stay in ICU and hospital: Comparison between the L-citrulline group and the placebo group

  9. Mortality

    Time frame: during the stay in hospital, up to 28 days

    • Mortality in intensive care and in hospital : Comparison between the L-citrulline group and the placebo group
    • Duration of mechanical ventilation.
  10. Duration of mechanical ventilation

    Time frame: during the stay in ICU, an average of 7 days

    Duration of mechanical ventilation: Comparison between the L-citrulline group and the placebo group

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: Immunocitre

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Aug 11, 2016
Registry last updated
Jun 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.